| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BSXBoston Scientific Corporation | 139.56B | 94.14 | 75.31 | 17.61% | 13.53% | 11.04% | 1.9% | 0.51 |
| MDTMedtronic plc | 123.61B | 96.42 | 26.71 | 3.62% | 13.71% | 9.75% | 4.19% | 0.59 |
| ITGRInteger Holdings Corporation | 2.9B | 82.74 | 24.34 | 10.35% | 4.75% | 4.98% | 3.44% | 0.68 |
| ADGMAdagio Medical Holdings, Inc. | 18.68M | 0.88 | -0.25 | -10.33% | -199.86% | -270% | 0.82 | |
| VTAKCatheter Precision, Inc. | 3.42M | 2.05 | -0.31 | -4.98% | -23.81% | -269.53% | 0.15 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 270K | 189K | 300K | 269K |
| Revenue Growth % | - | -0.3% | 0.59% | -0.1% |
| Cost of Goods Sold | 1.16M | 875K | 1.31M | 1.94M |
| COGS % of Revenue | 4.29% | 4.63% | 4.35% | 7.2% |
| Gross Profit | -888K | -686K | -1.01M | -1.67M |
| Gross Margin % | -3.29% | -3.63% | -3.35% | -6.2% |
| Gross Profit Growth % | - | 0.23% | -0.47% | -0.66% |
| Operating Expenses | 19.76M | 23.23M | 26.94M | 60.81M |
| OpEx % of Revenue | 73.17% | 122.89% | 89.79% | 226.07% |
| Selling, General & Admin | 4.4M | 5.37M | 11.54M | 6.98M |
| SG&A % of Revenue | 16.3% | 28.42% | 38.46% | 25.93% |
| Research & Development | 15.36M | 17.86M | 15.4M | 4.63M |
| R&D % of Revenue | 56.87% | 94.47% | 51.33% | 17.23% |
| Other Operating Expenses | 0 | 0 | 0 | 49.2M |
| Operating Income | -20.64M | -23.91M | -27.94M | -62.48M |
| Operating Margin % | -76.46% | -126.52% | -93.14% | -232.27% |
| Operating Income Growth % | - | -0.16% | -0.17% | -1.24% |
| EBITDA | -20.31M | -23.42M | -27.41M | -70.09M |
| EBITDA Margin % | -75.22% | -123.9% | -91.37% | -260.57% |
| EBITDA Growth % | - | -0.15% | -0.17% | -1.56% |
| D&A (Non-Cash Add-back) | 336K | 495K | 532K | -7.61M |
| EBIT | -19.94M | -23.54M | -27.94M | -54.87M |
| Net Interest Income | 3K | -98K | -1.66M | 1.52M |
| Interest Income | 3K | 39K | 3K | 423K |
| Interest Expense | 0 | 137K | 1.66M | -1.1M |
| Other Income/Expense | 707K | 240K | -10.2M | 8.72M |
| Pretax Income | -19.94M | -23.67M | -38.15M | -53.76M |
| Pretax Margin % | -73.84% | -125.25% | -127.15% | -199.86% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% |
| Net Income | -19.94M | -23.67M | -38.15M | -53.76M |
| Net Margin % | -73.84% | -125.25% | -127.15% | -199.86% |
| Net Income Growth % | - | -0.19% | -0.61% | -0.41% |
| Net Income (Continuing) | -19.94M | -23.67M | -38.15M | -53.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.34 | 0.06 | -4.86 | -3.54 |
| EPS Growth % | - | 1.16% | -88.41% | 0.27% |
| EPS (Basic) | -0.34 | 0.06 | -4.86 | -3.54 |
| Diluted Shares Outstanding | 19.19M | 19.19M | 7.86M | 15.2M |
| Basic Shares Outstanding | 19.19M | 19.19M | 7.86M | 15.2M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 19.72M | 6.73M | 5.18M | 25.35M |
| Cash & Short-Term Investments | 18.85M | 5.55M | 1.38M | 20.59M |
| Cash Only | 18.85M | 5.55M | 1.38M | 20.59M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 33K | 0 | 71K | 35K |
| Days Sales Outstanding | 44.61 | - | 86.38 | 47.49 |
| Inventory | 334K | 367K | 3.32M | 2.57M |
| Days Inventory Outstanding | 105.28 | 153.09 | 928.43 | 483.53 |
| Other Current Assets | 241K | 527K | 177K | 222K |
| Total Non-Current Assets | 1.72M | 1.97M | 1.64M | 23.1M |
| Property, Plant & Equipment | 1.7M | 1.94M | 1.62M | 2.15M |
| Fixed Asset Turnover | 0.16x | 0.10x | 0.19x | 0.13x |
| Goodwill | 0 | 0 | 0 | 13.97M |
| Intangible Assets | 0 | 0 | 0 | 6.97M |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 22K | 26K | 23K | 14K |
| Total Assets | 21.44M | 8.7M | 6.83M | 48.45M |
| Asset Turnover | 0.01x | 0.02x | 0.04x | 0.01x |
| Asset Growth % | - | -0.59% | -0.22% | 6.1% |
| Total Current Liabilities | 2.59M | 12.97M | 47.18M | 7.76M |
| Accounts Payable | 578K | 1.01M | 3.83M | 2.84M |
| Days Payables Outstanding | 182.18 | 421.73 | 1.07K | 535.16 |
| Short-Term Debt | 0 | 9.5M | 38.13M | 143K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 843K | 0 | 1.64M | 2.16M |
| Current Ratio | 7.62x | 0.52x | 0.11x | 3.27x |
| Quick Ratio | 7.49x | 0.49x | 0.04x | 2.93x |
| Cash Conversion Cycle | -32.3 | - | -55.59 | -4.14 |
| Total Non-Current Liabilities | 91.47M | 91.61M | 91.67M | 20.77M |
| Long-Term Debt | 0 | 0 | 143K | 16.08M |
| Capital Lease Obligations | 0 | 134K | 52K | 46K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 883K |
| Other Non-Current Liabilities | 91.47M | 91.47M | 91.48M | 3.77M |
| Total Liabilities | 94.06M | 104.57M | 138.85M | 28.54M |
| Total Debt | 0 | 9.8M | 38.4M | 16.27M |
| Net Debt | -18.85M | 4.25M | 37.02M | -4.32M |
| Debt / Equity | - | - | - | 0.82x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | - | -174.55x | -16.84x | - |
| Total Equity | -72.62M | -95.88M | -132.02M | 19.91M |
| Equity Growth % | - | -0.32% | -0.38% | 1.15% |
| Book Value per Share | -3.78 | -5.00 | -16.81 | 1.31 |
| Total Shareholders' Equity | -72.62M | -95.88M | -132.02M | 19.91M |
| Common Stock | 1K | 1K | 1K | 2K |
| Retained Earnings | -73.39M | -97.06M | -133.65M | -70.59M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | 28K | 17K | 1K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -19.31M | -22.41M | -25.65M | -29.46M |
| Operating CF Margin % | -71.51% | -118.58% | -85.51% | -109.51% |
| Operating CF Growth % | - | -0.16% | -0.14% | -0.15% |
| Net Income | -19.94M | -23.67M | -36.59M | -75.04M |
| Depreciation & Amortization | 336K | 495K | 548K | 1.39M |
| Stock-Based Compensation | 339K | 0 | 442K | 0 |
| Deferred Taxes | 0 | 0 | 0 | -1.92M |
| Other Non-Cash Items | -623K | 436K | 9.98M | 40.33M |
| Working Capital Changes | 579K | 330K | -32K | 5.79M |
| Change in Receivables | 40K | 33K | -70K | 35K |
| Change in Inventory | -473K | 35K | -2.98M | 626K |
| Change in Payables | 279K | 436K | 0 | -4.56M |
| Cash from Investing | -1.27M | -500K | -340K | -1.65M |
| Capital Expenditures | -1.26M | -502K | -333K | -1.65M |
| CapEx % of Revenue | 4.66% | 2.66% | 1.11% | 6.13% |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | -14K | 0 | -7K | 0 |
| Cash from Financing | 130K | 9.53M | 21.88M | 15.63M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | 130K | 0 | 18K | 0 |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -20.58M | -22.9M | -25.98M | -31.11M |
| FCF Margin % | -76.22% | -121.19% | -86.62% | -115.64% |
| FCF Growth % | - | -0.11% | -0.13% | -0.2% |
| FCF per Share | -1.07 | -1.19 | -3.31 | -2.05 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.95x | 0.67x | 0.55x |
| Interest Paid | 0 | 0 | 208K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -270% |
| Gross Margin | -328.89% | -362.96% | -335.33% | -620.07% |
| Net Margin | -7384.44% | -12525.4% | -12715.33% | -19986.25% |
| Debt / Equity | - | - | - | 0.82x |
| Interest Coverage | - | -174.55x | -16.84x | - |
| FCF Conversion | 0.97x | 0.95x | 0.67x | 0.55x |
| Revenue Growth | - | -30% | 58.73% | -10.33% |
Adagio Medical Holdings, Inc. (ADGM) reported $-0.1M in revenue for fiscal year 2024. This represents a 153% decrease from $0.3M in 2021.
Adagio Medical Holdings, Inc. (ADGM) saw revenue decline by 10.3% over the past year.
Adagio Medical Holdings, Inc. (ADGM) reported a net loss of $74.6M for fiscal year 2024.
Adagio Medical Holdings, Inc. (ADGM) has a return on equity (ROE) of -270.0%. Negative ROE indicates the company is unprofitable.
Adagio Medical Holdings, Inc. (ADGM) had negative free cash flow of $23.6M in fiscal year 2024, likely due to heavy capital investments.